Authors' recommendations: RESULTS The RR and the DFS, followed by TTP, are the surrogate variables most frequently analyzed in the RCTs conducted on ABC or MBC. Regarding the correlation between the surrogate variables and the OS, the results of this study show that first-line chemotherapy in patients with ABC or MBC, and considering only MBC patients, a weak relationship exists between the surrogate variable DFS and the OS. The surrogate variables that correlated best with the OS, in ABC or MBC and considering MBC only, are the TTP and RR. Several studies have evaluated the correlation between treatment effect on the OS and on the potential surrogate variables in ABC or MBC and considering only patients with MBC. In patients in firstline treatment for MBC, the RR, the DFS and the TTP showed a moderate association with the OS. CONCLUSION The use of the variables TTP and RR in RCTs that evaluate the efficacy of anticancer drugs in first-line chemotherapy in patients with ABC or MBC may be appropriate, although it is important to consider the magnitude of their variations.

Project Status: Completed

URL for project: https://www.aetsa.org/publicacion/valoracion-de-variables-subrogadas-en-oncologia/

Year Published: 2011

URL for published report: https://www.aetsa.org/download/publicaciones/antiguas/AETSA_2009-12_VariableSubrogadas.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Spain

Organisation Name: Andalusian Health Technology Assessment Area

Contact Address: Area de Evaluacion de Tecnologias Sanitarias Sanitarias de Andalucia (AETSA) Avda. Innovación, s/n Edificio Arena 1. Sevilla (Spain) Tel. +34 955 006 309

Contact Name: aetsa.csalud@juntadeandalucia.es

Contact Email: aetsa.csalud@juntadeandalucia.es

Copyright: Andalusian Agency for Health Technology Assessment (AETSA)